Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update
Retrieved on:
Friday, May 19, 2023
Amgen, US Foods, Corporate sustainability, Blas, Medication, Adalimumab, Pharmacokinetics, Omalizumab, G&A, Absorption, IP, Bristol Myers Squibb, Biologics license application, Rheumatoid arthritis, US, Patient, AbbVie, Webcast, OPMA, CRL, Biosimilar, R, FDA, Environment, BLA, Safety, Generic drug, Flour, Pharmaceutical industry, Online shopping, Cryptocurrency, Icelandic króna, News
In May 2023, a confirmatory patient study was initiated for AVT05, a proposed biosimilar to Simponi® and Simponi Aria® (golimumab).
Key Points:
- In May 2023, a confirmatory patient study was initiated for AVT05, a proposed biosimilar to Simponi® and Simponi Aria® (golimumab).
- In March 2023, Alvotech provided an update on the company’s Corporate Sustainability Framework that included new disclosures for 2022.
- R&D expenses were $50.9 million for the three months ended March 31, 2023, compared to $47.1 million for the same three months of 2022.
- Alvotech will conduct a business update conference call and live webcast on Friday, May 19, at 8:00 am ET (12:00 noon GMT).